The Serum Institute of India (SII) has called on the government to accelerate the Covishield movement, citing difficulties in manufacturing and planning cold chain space for other vaccines due to increased vaccine stockpiles. COVID-19 jab, officials said Sunday.
It was reported that Prakash Kumar Singh, SII’s director of government and regulatory affairs, recently told the Union Ministry of Health that its production stock is 24,89,15,000 doses of Covishield and is increasing every day.
Singh reportedly told the ministry that in addition to the Covishield vaccine, the Pune-based company also manufactures and supplies various rescue vaccines for EPI, UNICEF and other countries.
“In order to meet our supply commitments in the domestic and international markets, we must plan ahead for our production / cold chain space / human resources. With the continuous expansion of Covishield stocks, we are facing many challenges in manufacturing / cold chain space / human resource planning for other life-saving vaccines, ”Singh was quoted as saying in the letter.
“In view of these facts, real difficulties and as this issue is directly related to the availability of various other life-saving vaccines in our country and in the world in general, we ask for your kind intervention to accelerate the promotion of our Covishield vaccine. domestically and worldwide, ”Singh said.
The center allowed SII to export 50 lakh doses of Covishied under the UN-backed COVAX global vaccine exchange program to Nepal, Tajikistan and Mozambique. SII will also export Covishield to Bangladesh under COVAX, an official said.
The Serum Institute will begin exporting the Covid vaccine under the COVAX program from 23 November, and Nepal will receive the first shipment of Covishiled vaccine on 24 November.
In October, the government authorized SII to export 10,000 doses of Covishield to Nepal, Myanmar and Bangladesh under the Maitri Vaccine program.